Sanyou Biopharmaceuticals Co., Ltd. (Sanyou Bio), a world-leading biotechnology company specializing in innovative biologic drug research and development, has completed a full review of its Intelligent Super-Trillion Molecule Discovery Platform. As the platform's core technology, the intelligent super-trillion molecule library boasts a capacity of up to 10 trillion molecules, enabling the screening and identification of hundreds to thousands of lead molecules for a single target. By integrating high-throughput eukaryotic expression verification and multidimensional druggability analysis, this cutting-edge platform significantly enhances the efficiency of biologic drug discovery and plays a pivotal role in novel macromolecule drug development.

A Breakthrough in Drug Discovery

Sanyou Bio's Intelligent Super-Trillion Molecule Discovery Platform comprises ten specialized sub-platforms, each targeting distinct molecular types. These include:

• Super-trillion fully human antibody discovery platform

• Super-trillion common light chain antibody discovery platform

• Super-trillion 2C type single-domain antibody discovery platform

• Super-trillion 4C type single-domain antibody discovery platform

• Super-trillion cyclic peptide discovery platform

• Super-trillion novel targeting protein discovery platform

• Magnetic-array mouse immune antibody discovery platform

• Magnetic-array alpaca immune antibody discovery platform

• Magnetic-array rabbit immune antibody discovery platform

• Magnetic-array canine immune antibody discovery platform

Each sub-platform offers unique characteristics tailored to therapeutic, diagnostic, detection, and scientific research applications. Since its inception, the Intelligent Super-Trillion Molecule Discovery Platform has successfully completed over 650 molecule discovery projects, advancing more than 100 Preclinical Candidate (PCC) projects—some of which have already entered the clinical stage. This achievement underscores Sanyou Bio's capability in pioneering the development of monoclonal antibodies, bispecific and multispecific antibody drugs, ADCs, AOCs, RDCs, PDCs, and CAR-T immune cell therapies.

Pioneering a New Era in Biopharmaceutical Research

As part of its commitment to continuous innovation, Sanyou Bio is set to expand its platform by developing a 100-Trillion Molecule Library. This next-generation platform will incorporate nucleic acid, small peptide, and small molecule libraries, further diversifying the discovery of novel therapeutics. AI-driven molecular design, sequence optimization, and high-throughput screening technologies will be integrated to significantly accelerate drug discovery timelines, enhance success rates, and optimize drug development pipelines.

The Future of AI-Driven Drug Discovery

Sanyou Bio is also advancing the development of an intelligent drug screening platform powered by generative AI models. This initiative aims to revolutionize antibody drug discovery by:

1. De novo molecular generation, breaking traditional drug discovery constraints and enabling first-in-class therapeutics.

2. AI-powered coding sequence optimization, improving druggability and stability.

3. Next-generation molecular library design, enhancing efficiency in screening and molecule identification for complex targets such as GPCRs, ion channels, and intracellular proteins.

Shaping the Future of Global Biologic Drug Development

After a decade of relentless innovation, Sanyou Bio’s Intelligent Super-Trillion Molecule Discovery Platform has become a world-class antibody drug discovery system. With its comprehensive library design and advanced screening technologies, the platform has overcome key challenges in innovative macromolecule drug discovery, offering unprecedented opportunities in oncology, infectious disease treatment, autoimmune disorders, and rare diseases.

Looking ahead, Sanyou Bio aims to accelerate the global development of next-generation biologics by further enhancing AI-driven screening, high-throughput analysis, and collaborative research initiatives. Through strategic partnerships with global biopharmaceutical companies, drug R&D institutions, and diagnostics firms, the company is dedicated to delivering breakthrough treatments to patients worldwide.